Discovery of Adamantyl Heterocyclic Ketones as Potent 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors
2011

Discovery of Potent Inhibitors for a Key Enzyme in Metabolic Syndrome

publication Evidence: high

Author Information

Author(s): Su Xiangdong, Vicker Nigel, Thomas Mark P, Pradaux-Caggiano Fabienne, Halem Heather, Culler Michael D, Potter Barry V L

Primary Institution: University of Bath

Hypothesis

Can adamantyl heterocyclic ketones serve as effective inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1?

Conclusion

The study identified several adamantyl heterocyclic ketones as potent and selective inhibitors of 11β-HSD1, which may help in treating metabolic syndrome.

Supporting Evidence

  • Lead compounds displayed low nanomolar inhibition against human and mouse 11β-HSD1.
  • Selected inhibitors showed moderate metabolic stability in human liver microsomes.
  • Compounds were tested for selectivity against other hydroxysteroid dehydrogenases.

Takeaway

Scientists found new compounds that can block a specific enzyme linked to obesity and diabetes, which could help people with these conditions.

Methodology

The study involved synthesizing and testing various adamantyl heterocyclic ketones for their inhibitory effects on 11β-HSD1 using cell-based assays.

Digital Object Identifier (DOI)

10.1002/cmdc.201100144

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication